sellWeak10b5-1 plan
Stephen F. Betz sold $3.1M of CRNX
Chief Scientific Officer at Crinetics Pharmaceuticals, Inc.. 97,483 shares at an average of $32.23, traded Jun 12, 2025, filed Jun 16, 2025.
Warning score
15Value
$3.1M
97,483 shares
Holdings after
99,713
-49% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$3.1M at market
- +10Share of holdings soldSold 49% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-086804, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 12, 2025 | MOption exercise Common Stock10b5-1 | +71,525 | $1.91 | $137k | 180,551 | Jun 16, 2025 |
| Jun 12, 2025 | MOption exercise Common Stock10b5-1 | +16,645 | $9.28 | $154k | 197,196 | Jun 16, 2025 |
| Jun 12, 2025 | SOpen-market sale Common Stock10b5-1 | -97,483 | $32.23 | $3.1M | 99,713 | Jun 16, 2025 |
| Jun 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -71,525 | $0.00 | $0 | 108,514 | Jun 16, 2025 |
| Jun 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,645 | $0.00 | $0 | 58,198 | Jun 16, 2025 |
Related signals
Other insiders at Crinetics Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $197k 5,770 shares | -5% | |
| 39Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $593k 17,338 shares | -5% | |
| 28Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $245k 7,162 shares | -8% | |
| 19Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $86k 2,515 shares | -3% | |
| 0Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $195k 5,000 shares | -14% | |
| 12Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $781k 15,000 shares | -34% | |
| 32Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $576k 10,000 shares | -9% | |
| 13Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $28k 501 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.